AR075262A1 - Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para - Google Patents
Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos paraInfo
- Publication number
- AR075262A1 AR075262A1 ARP090102880A ARP090102880A AR075262A1 AR 075262 A1 AR075262 A1 AR 075262A1 AR P090102880 A ARP090102880 A AR P090102880A AR P090102880 A ARP090102880 A AR P090102880A AR 075262 A1 AR075262 A1 AR 075262A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- cycloalkyl
- branched
- linear
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title 1
- 229960003987 melatonin Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- -1 CHFCH3 Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- VWPZCDAKAYFFLM-UHFFFAOYSA-N 2,6-dihydro-1h-furo[3,2-e]indole Chemical compound O1CCC2=C1C=CC1=C2C=CN1 VWPZCDAKAYFFLM-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161485 | 2008-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075262A1 true AR075262A1 (es) | 2011-03-23 |
Family
ID=41138660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102880A AR075262A1 (es) | 2008-07-30 | 2009-07-29 | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8227501B2 (OSRAM) |
| EP (1) | EP2350088A1 (OSRAM) |
| JP (1) | JP2011529477A (OSRAM) |
| KR (1) | KR20110041495A (OSRAM) |
| CN (1) | CN102112480A (OSRAM) |
| AR (1) | AR075262A1 (OSRAM) |
| AU (1) | AU2009275918A1 (OSRAM) |
| BR (1) | BRPI0916395A2 (OSRAM) |
| CA (1) | CA2731405A1 (OSRAM) |
| CL (1) | CL2011000184A1 (OSRAM) |
| MX (1) | MX2011001062A (OSRAM) |
| PE (1) | PE20110208A1 (OSRAM) |
| RU (1) | RU2011107443A (OSRAM) |
| TW (1) | TW201018695A (OSRAM) |
| UY (1) | UY32016A (OSRAM) |
| WO (1) | WO2010012789A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| AR091699A1 (es) * | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| CN104109143B (zh) * | 2013-04-22 | 2018-04-27 | 上海阳帆医药科技有限公司 | 一类褪黑激素(mt1-mt2)受体激动剂及其制备方法与用途 |
| CN104326916B (zh) * | 2014-10-10 | 2017-09-22 | 青岛农业大学 | 2‑氟‑4‑烯丙基‑6‑硝基苯酚与2‑氟‑4‑硝基‑6‑烯丙基苯酚的联合制备及用途 |
| PE20190467A1 (es) | 2016-06-17 | 2019-04-04 | Dae Woong Pharma | Metodo para producir derivado de difenilmetano |
| CN118696029A (zh) * | 2021-12-24 | 2024-09-24 | 普赛洛私人有限公司 | 化合物 |
| KR20240044190A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 결정형 및 이의 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3466215D1 (en) * | 1983-05-18 | 1987-10-22 | Univ Monash | The use of melatonin for the manufacture of a medicament |
| US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| WO1989001472A1 (en) | 1987-08-17 | 1989-02-23 | Nelson Research & Development Co. | Melatonin analogues |
| FR2680366B1 (fr) * | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) * | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| DE69633289T2 (de) * | 1995-06-27 | 2006-01-12 | Takeda Pharmaceutical Co. Ltd. | 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten |
| US5732360A (en) | 1995-09-08 | 1998-03-24 | At & T Wireless Services And Atmel Corp | Mobile telecommunication device and method used for changing wireless communication between base stations of different kinds |
| KR100494214B1 (ko) | 1996-03-08 | 2005-11-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 삼환화합물,그의제조방법및용도 |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| FR2771739B1 (fr) * | 1997-11-28 | 2001-04-20 | Adir | Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2784375B1 (fr) * | 1998-10-12 | 2000-11-24 | Adir | Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2793793B1 (fr) * | 1999-05-19 | 2004-02-27 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE443526T1 (de) | 1999-08-20 | 2009-10-15 | Takeda Pharmaceutical | Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff |
| FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6737431B2 (en) * | 2002-03-12 | 2004-05-18 | Bristol-Myers Squibb Company | Benzoxazole derivatives as novel melatonergic agents |
| ES2336664T3 (es) * | 2002-06-21 | 2010-04-15 | Suven Life Sciences Limited | Arilaquil indoles que tienen afinidad por receptores de serotonina utiles como agentes terapeuticos, procesos para su preparacion y composiciones farmaceuticas que los contienen. |
| US6908931B2 (en) * | 2003-04-10 | 2005-06-21 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists |
| WO2005062992A2 (en) | 2003-12-23 | 2005-07-14 | Abraxis Bioscience, Inc | Substituted melatonin derivatives, process for their preparation, and methods of use |
-
2009
- 2009-07-29 AU AU2009275918A patent/AU2009275918A1/en not_active Abandoned
- 2009-07-29 CA CA2731405A patent/CA2731405A1/en not_active Abandoned
- 2009-07-29 AR ARP090102880A patent/AR075262A1/es unknown
- 2009-07-29 BR BRPI0916395A patent/BRPI0916395A2/pt not_active IP Right Cessation
- 2009-07-29 EP EP09781255A patent/EP2350088A1/en not_active Withdrawn
- 2009-07-29 CN CN2009801300227A patent/CN102112480A/zh active Pending
- 2009-07-29 MX MX2011001062A patent/MX2011001062A/es active IP Right Grant
- 2009-07-29 UY UY0001032016A patent/UY32016A/es unknown
- 2009-07-29 KR KR1020117002324A patent/KR20110041495A/ko not_active Withdrawn
- 2009-07-29 JP JP2011520509A patent/JP2011529477A/ja not_active Abandoned
- 2009-07-29 US US13/056,492 patent/US8227501B2/en not_active Expired - Fee Related
- 2009-07-29 RU RU2011107443/04A patent/RU2011107443A/ru not_active Application Discontinuation
- 2009-07-29 WO PCT/EP2009/059829 patent/WO2010012789A1/en not_active Ceased
- 2009-07-29 TW TW098125512A patent/TW201018695A/zh unknown
- 2009-07-29 PE PE2011000041A patent/PE20110208A1/es not_active Application Discontinuation
-
2011
- 2011-01-28 CL CL2011000184A patent/CL2011000184A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011107443A (ru) | 2012-09-10 |
| US20110144178A1 (en) | 2011-06-16 |
| EP2350088A1 (en) | 2011-08-03 |
| AU2009275918A1 (en) | 2010-02-04 |
| CA2731405A1 (en) | 2010-02-04 |
| JP2011529477A (ja) | 2011-12-08 |
| CL2011000184A1 (es) | 2011-09-16 |
| MX2011001062A (es) | 2011-03-24 |
| CN102112480A (zh) | 2011-06-29 |
| WO2010012789A1 (en) | 2010-02-04 |
| UY32016A (es) | 2010-01-29 |
| PE20110208A1 (es) | 2011-03-28 |
| KR20110041495A (ko) | 2011-04-21 |
| US8227501B2 (en) | 2012-07-24 |
| BRPI0916395A2 (pt) | 2016-02-16 |
| TW201018695A (en) | 2010-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075262A1 (es) | Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno, proceso para prepararlos, composicion farmaceutica que los comprende, sus usos como medicamentos, o en tratamientos o prevenciones de condiciones asociadas con un funcionamiento alterado de los sistemas regulados por la melatonina, sus usos para | |
| ES2477940T3 (es) | Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria | |
| AR088668A1 (es) | Moleculas pequeñas que contienen boro | |
| CO6241076A2 (es) | Compuestos de benzamida y aplicaciones de los mismos | |
| MX343611B (es) | Composicion de control de fitoenfermedades y su uso. | |
| PE20180030A1 (es) | Compuestos biciclicos de sulfonamida cetona | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| AR088669A1 (es) | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos | |
| AR098912A1 (es) | Inhibidores de syk | |
| PE20142282A1 (es) | Nuevos derivados de aril-quinolina | |
| CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| AR077080A1 (es) | Compuestos de 2,3-dihidro-1h-indeno | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
| AR078606A1 (es) | Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central | |
| MX2015016971A (es) | Formulacion que comprende un agente hipolipidemico. | |
| AR099047A1 (es) | Derivados etinilo | |
| AR059710A1 (es) | Arilsulfonamidas sustituidas | |
| AR080249A1 (es) | Compuestos en calidad de antagonistas de bradiquinina-b1 | |
| AR081908A1 (es) | N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas | |
| AR104331A1 (es) | Derivados de tetrazol | |
| PE20141113A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| AR096165A1 (es) | Síntesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin-2,6-diona | |
| AR075915A1 (es) | Proceso para la obtencion de derivados de acido propionico | |
| EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |